ACLX
Price:
$76.79
Market Cap:
$4.15B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known...[Read more]
Industry
Biotechnology
IPO Date
2022-02-04
Stock Exchange
NASDAQ
Ticker
ACLX
According to Arcellx, Inc.’s latest financial reports and current stock price. The company's current ROE is -8.28%. This represents a change of 299.16% compared to the average of -2.08% of the last 4 quarters.
The mean historical ROE of Arcellx, Inc. over the last ten years is -1.17%. The current -8.28% ROE has changed 609.25% with respect to the historical average. Over the past ten years (40 quarters), ACLX's ROE was at its highest in in the December 2021 quarter at 17.01%. The ROE was at its lowest in in the September 2022 quarter at -39.31%.
Average
-1.17%
Median
17.90%
Minimum
-90.80%
Maximum
54.90%
Discovering the peaks and valleys of Arcellx, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.45%
Maximum Annual ROE = 54.90%
Minimum Annual Increase = -272.59%
Minimum Annual ROE = -90.80%
Year | ROE | Change |
---|---|---|
2023 | -14.56% | -83.96% |
2022 | -90.80% | -272.59% |
2021 | 52.61% | 4.45% |
2020 | 50.37% | -8.25% |
2019 | 54.90% | -192.24% |
The current ROE of Arcellx, Inc. (ACLX) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-17.59%
5-year avg
10.50%
10-year avg
-1.17%
Arcellx, Inc.’s ROE is greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Biomea Fusion, Inc. (-118.90%),
Company | ROE | Market cap |
---|---|---|
-28.63% | $5.96B | |
-54.94% | $166.17M | |
-85.39% | $278.99M | |
-22.40% | $1.28B | |
-118.90% | $146.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcellx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcellx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Arcellx, Inc.'s ROE?
How is the ROE calculated for Arcellx, Inc. (ACLX)?
What is the highest ROE for Arcellx, Inc. (ACLX)?
What is the 3-year average ROE for Arcellx, Inc. (ACLX)?
What is the 5-year average ROE for Arcellx, Inc. (ACLX)?
How does the current ROE for Arcellx, Inc. (ACLX) compare to its historical average?